Diagnostics News and Research

RSS

Orthopedics This Week presents 2010 Spine Technology Awards to Axial Biotech

Axial Biotech, Inc., a company revolutionizing spine care through the development of molecular diagnostic technologies, was selected as a winner at the 2010 Spine Technology Awards.

5 Oct 2010

Sirius Genomics signs second Contribution Agreement with NRC-IRAP

Sirius Genomics, a developer of companion diagnostics, announced today that it has signed its second Contribution Agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).

5 Oct 2010

CardioDx publishes PREDICT trial results

CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced publication of results from the Personalized Risk Evaluation and Diagnosis In the Coronary Tree (PREDICT) trial in the Annals of Internal Medicine, the journal of the American College of Physicians.

5 Oct 2010

cobas TaqScreen DPX Test now available with CE Mark: Roche

Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available with the CE Mark. It is the first IVD test to offer complete coverage of all human genotypes of parvovirus B19 (B19V) and hepatitis A virus (HAV) in one assay.

5 Oct 2010

CHI submits comments to FDA CDRH 510(k) Working Group Preliminary Report and Recommendations

California Healthcare Institute today submitted formal comments to the U.S. Food and Drug Administration (FDA) regarding the Center for Devices and Radiological Health 510(k) Working Group Preliminary Report and Recommendations, which could transform the 510(k) regulatory process for new medical devices, greatly affecting innovation and public health in California. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.

5 Oct 2010

NIH to award $64M under Transformative Research Projects program

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.

4 Oct 2010

Breast cancer breakthrough

New research on gene expression provides a breakthrough in breast cancer treatment. Women who have triple-negative breast cancer are a small proportion of breast cancer cases, but it is difficult to treat and might have a more aggressive clinical course than other forms of the disease.

30 Sep 2010

Prix Galien USA committee honors life saving innovations

The Prix Galien USA committee honored innovations that are saving lives last night during the Prix Galien Awards Gala. The Pro Bono Humanum Award, the Prix Galien USA 2010 and the Prix Galien International were presented and related accomplishments celebrated.

30 Sep 2010

Penn Medicine selected as study site for PPMI

The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.

30 Sep 2010

AccuPSA test for detecting prostate cancer recurrence

A new test could reliably detect early increases in prostate specific antigen (PSA) levels a biomarker commonly used to measure the recurrence of prostate cancer in men who have undergone prostate cancer treating surgery. Earlier detection of these rising levels would allow men with cancer recurrence to undergo earlier, more effective treatment for potentially better outcomes.

30 Sep 2010

New miRNA screening assay to detect early-stage colorectal cancer

A new microRNA (miRNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity. Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup,said Søren Jensby Nielsen, Ph.D., scientific manager, Diagnostic Product Development, Exiqon A/S

30 Sep 2010

MicroRNAs assay may allow better targeted therapy for lung cancer patients

A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.

30 Sep 2010

Radiologists urge judicious use of radiation-based imaging in children

A CT scan can mean the difference between an accurate and a wrong diagnosis, timely and delayed treatment and, in some cases, life and death. But because CT scans and other tests that use X-ray technology expose the body to often large doses of radiation, their unnecessary, repeated and excessive use may increase cancer risk, especially in children.

30 Sep 2010

Researchers develop C5 technology to identify CTCs in breast cancer

Researchers have identified a novel, dual-platform technology, the On-Q-ity Circulating Cancer Capture and Characterization Chip (C5), which they believe is more efficient than the commonly used single-platform device in identifying circulating tumor cells (CTCs) in breast cancer.

30 Sep 2010

U.N. agencies' report examines global progress in fight against HIV/AIDS

"A record 1.2 million people in low- and middle-income countries started antiretroviral therapy for HIV/AIDS in 2009" - a 30 percent increase from the previous year and a 13-fold increase in six years, according to a joint report released Tuesday by the WHO, UNICEF and UNAIDS, Reuters reports. In total, the report found that 5.25 million people received antiretroviral therapy (ART) in 2009, three-quarters of them living in Africa (Migiro, 9/28).

30 Sep 2010

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

Circadian Technologies (ASX.CIR) has announced today that it has partnered with Cincinnati Children’s Hospital Medical Centre (CCHMC) to develop and market a blood test to diagnose LAM, a serious lung disease that strikes women, usually in their child bearing years.

29 Sep 2010

Unique genetic markers point to patient response to SCV-07 treatment

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company’s phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer.

29 Sep 2010

Significant progress made universally in increasing access to HIV/AIDS services: Report

Significant progress has been made in several low- and middle-income countries in increasing access to HIV/AIDS services, according to a new report released today. The report Towards universal access by WHO, the United Nations Children's Fund and the Joint United Nations Programme on HIV/AIDS is the fourth annual report for tracking progress made in achieving the 2010 target of providing universal access to HIV prevention, treatment and care.

29 Sep 2010

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

29 Sep 2010

Circulating tumor cells may be promising alternative for tumor biopsies

Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010